The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis

Journal of Internal Medicine

Volumn 260, Issue 6, 2006, Pages 517-529

  Drevs, J ^a,b   Schneider, V ^a  

^a Tumorklinik Sanafontis   (Germany)

^b Tumorklinik SanaFontis ^*  (Germany)

Author keywords

Angiogenesis; Anti tumour; Imaging; Soluble markers

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; AZD 2171; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CARBON MONOXIDE C 11; CARBON MONOXIDE C 15; CARBOXYHEMOGLOBIN C 15; CONTRAST MEDIUM; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR TC 99M; FLUORODEOXYGLUCOSE F 18; FLUOROMETHANE F 18; GADOTERATE MEGLUMINE; IRON OXIDE; PROTEIN TYROSINE KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; REBIMASTAT; SUPERPARAMAGNETIC IRON OXIDE; TIE 1 RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2 PENTETATE INDIUM IN 111; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VATALANIB; VITRONECTIN RECEPTOR; WATER O 15;

ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; DRUG TARGETING; HUMAN; IMAGING; KIDNEY CARCINOMA; MAXIMUM TOLERATED DOSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; TUMOR VASCULARIZATION; ULTRASOUND; WOUND HEALING;

ANGIOGENESIS INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE ANGIOGRAPHY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 33751078812     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01727.x     Document Type: Review

References (33)

1. Fabbro D, Buchdunger E, Wood J et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 1999; 82: 293-301.
2. Gille H, Kowalski J, Li B et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001; 276: 3222-30.
3. Autiero M, Waltenberger J, Communi D et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-43.
4. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002; 82: 673-700.
5. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 2005; 5: 735-43.
6. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004; 4 (Suppl. 2): S62-8.
7. Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004; 10 (12 Pt 2): 4258s-62s.
8. Miller KD, Miller M, Mehrotra S et al. A physiologic imaging pilot study of breast cancer treated with AZD2171. Clin Cancer Res 2006; 12: 281-8.
9. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11: 5472-80.
10. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 1-3.
11. Gayed I, Vu T, Iyer R et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45: 1803.
12. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7.
13. Lockhart AC, Braun RD, Yu D et al. Clinical model of dermal wound angiogenesis. Wound Repair Regen 2003; 11: 306-13.
14. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001; 7: 1992-7.
15. Wittig BM, Kaulen H, Thees R et al. Elevated serum E-selectin in patients with liver metastases of colorectal cancer. Eur J Cancer 1996; 32A: 1215-8.
16. Homer JJ, Greenman J, Drevs J, Marme D, Stafford ND. Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma. Head Neck 2002; 24: 773-8.
17. Klisch J, Kubalek R, Scheufler KM, Zirrgiebel U, Drevs J, Schumacher M. Plasma vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE-2 in patients with dural arteriovenous fistulas: a pilot study. Neuroradiology 2005; 47: 10-7.
18. Drevs J, Loser R, Rattel B, Esser N. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 2003; 23: 4853-8.
19. Drevs J, Medinger M, Mross K et al. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23: (Suppl.): Abstract No. 3002.
20. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005; 16: 558-65.
21. McCarville MB, Streck CJ, Dickson PV, Li CS, Nathwani AC, Davidoff AM. Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. Radiology 2006; 240: 73-81.
22. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000; 60: 4819-24.
23. Mross K, Drevs J, Muller M et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005; 41: 1291-9.
24. Ding B, Ling HW, Chen KM, Jiang H, Zhu YB. Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging. Neuroradiology 2006 [Epub ahead of print].
25. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006; 24: 3293-8.
26. Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-64.
27. Haberkorn U, Strauss LG, Reisser C et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991; 32: 1548-55.
28. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992; 52: 1592-7.
29. Wells P, Jones T, Price P. Assessment of inter- and intrapatient variability in C15O2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers. Clin Cancer Res 2003; 9: 6350-6.
30. Collingridge DR, Carroll VA, Glaser M et al. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 2002; 62: 5912-9.
31. Kobayashi H, Sakahara H, Hosono M et al. Scintigraphic detection of xenografted tumors producing human basic fibroblast growth factor. Cancer Immunol Immunother 1993; 37: 281-5.
32. Kulasegaram R, Giersing B, Page CJ et al. In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. Eur J Nucl Med 2001; 28: 756-61.
33. Beer AJ, Haubner R, Goebel M et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005; 46: 1333-41.